Download • - Cambridge Isotope Laboratories

For Immediate Release
October 1, 2007
Cambridge Isotope Laboratories, Inc. (CIL)
Cambridge Isotope Laboratories, Inc. Acquires
M-fold Biotech GmbH
Boston, Massachusetts: Cambridge Isotope Laboratories, Inc. (CIL), the world leader in
the manufacturing of stable isotope labeled research chemicals has acquired 100% of the
stock of M-fold Biotech GmbH, a biotech company located in Tuebingen, Germany
specializing in a proprietary method for folding proteins called M-fold.
The core business of M-fold is the manufacture, crystallization and structural analysis of
human membrane proteins or receptors. M-fold has developed methods for expressing
G protein-coupled receptors (GPCRs) in bacteria utilizing stable isotope labeled media
and refolding proteins into biologically active forms. GPCRs are involved in a wide
range of biological activities (blood pressure, pain cancer growth) and play a key role in a
number of diseases due to their importance in maintaining proper function of living cells.
These protein receptors are the targets of over 50% of all existing medicines including
well-known blockers and anti-histamine therapeutics.
M-fold Biotech was founded in March 2007 by Dr. Hans Kiefer as a successor company
of m-phasys GmbH, a six year biotechnology company. The M-FOLD™ technology for
the production of purified, functional membrane proteins is the basis of M-fold Biotech's
activities. The key managers and employees of M-fold are continuing with the Company.